| Bioactivity | Carotuximab (TRC105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions[1][2]. |
| Invitro | Carotuximab (TRC105；300 μg/mL；预处理 1 小时，然后共培养 12 小时) 降低人主动脉内皮细胞中 7-酮胆固醇诱导的内皮糖蛋白 (Eng) 蛋白水平和 pSmad1/5 和 pSmad2/3 信号通路。Carotuximab 介导的 Eng 阻断阻止了 7-酮胆固醇诱导的单核细胞通过内皮单层细胞的粘附和迁移[1]。 Western Blot Analysis[1] Cell Line: |
| In Vivo | Carotuximab（TRC105；2 mg/kg；i.v；每 3 天一次；持续 8 周）与 Decitabine 一起在急性髓性白血病 (AML) 异种移植物中产生更持久的抗白血病作用，并且还能增强活性氧 (ROS) 活性[2]。 Animal Model: |
| Name | Carotuximab |
| CAS | 1268714-50-6 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Katarina Tripska , et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med (Lausanne). 2022 Sep 7;9:845918. [2]. June Baik, et al. Therapeutic effect of TRC105 and decitabine combination in AML xenografts. Heliyon. 2020 Oct 13;6(10):e05242. |